Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Miconazole recalled?

Yes — there is an active recall. 4 ongoing FDA recalls mention Miconazole (18 total). Check the affected lots below.

Most common reason: Chemical / undeclared (8 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Miconazole. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Miconazole recalls in 2026

1 initiated in 2026, 18 in total — newest first
Class II · Moderate risk

DermaFungal

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-234-05 D-0162-2026
Class II · Moderate risk

Medline Remedy Clinical TREAT Antifungal Cream

Labeling: Not Elsewhere Classified; Product labeling contains the claim of 'Paraben Free' while the product does in fact contain parabens as part of the formulation/ ingredient list.

Ongoing Labeling / mix-up MEDLINE INDUSTRIES, LP - Northfield D-0315-2024
Class II · Moderate risk

Clinical TREAT Antifungal Powder

CGMP deviations: the product was shipped from the Manufacturer to a Medline warehouse and released to stock while it was still under investigation for low assay results on the active ingredient miconazole nitrate.

Terminated Wrong potency / content MEDLINE INDUSTRIES, LP - Northfield D-0091-2024
Class I · High risk

Lotrimin Af

Chemical Contamination: presence of benzene

Terminated Chemical / undeclared Bayer Healthcare Pharmaceuticals Inc. NDC 11523-0544-2 D-0248-2022
Class I · High risk

Lotrimin Af

Chemical Contamination: presence of benzene

Terminated Chemical / undeclared Bayer Healthcare Pharmaceuticals Inc. NDC 11523-4140-2 D-0247-2022
Class I · High risk

Lotrimin Af

Chemical Contamination: presence of benzene

Terminated Chemical / undeclared Bayer Healthcare Pharmaceuticals Inc. NDC 11523-1272-2 D-0246-2022
Class II · Moderate risk

Lotrimin AF

cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.

Terminated Chemical / undeclared Bayer Healthcare Pharmaceuticals Inc. NDC 11523-4327-1 D-0241-2022
Class II · Moderate risk

Lotrimin Af

cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.

Terminated Chemical / undeclared Bayer Healthcare Pharmaceuticals Inc. NDC 11523-0544-2 D-0238-2022
Class II · Moderate risk

Lotrimin Af

cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.

Terminated Chemical / undeclared Bayer Healthcare Pharmaceuticals Inc. NDC 11523-4140-2 D-0237-2022
Class II · Moderate risk

Lotrimin Af

cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.

Terminated Chemical / undeclared Bayer Healthcare Pharmaceuticals Inc. NDC 11523-1272-2 D-0236-2022
Class III · Low risk

Zeasorb AF

Labeling Not Elsewhere Classified: front labels have the incorrect NDC or 0145-1506-01 instead of the correct NDC of 0145-1506-05 and some back labels have the incorrect indication stating "use for the cure of most jock itch" rather than "use for the cure of most athlete's foot".

Terminated Labeling / mix-up GSK Consumer Healthcare NDC 0145-1506-01 D-0142-2017
Class III · Low risk

Monistat 1 Simple Cure

Marketed without an approved NDA/ANDA: The distributed units of Monistat 1 Simple Cure include only the 1200 mg vaginal suppository; the approved NDA requires both a 1200 mg vaginal suppository and the 2% topical cream.

Terminated Unapproved drug Medtech Products, Inc. NDC 63736-013-30 D-1077-2015
Class II · Moderate risk

Miconazole Nitrate active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-797-2015
Class II · Moderate risk

Miconazole 3% Injection

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-761-2013